The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine H1 receptor

European Journal of Pharmacology

Volume 838, 5 November 2018, Pages 107-111

Full length article

Author links open overlay panelReggieBosmaaJellevan den BoraHenry F.VischeraLuisLabeagabRobLeursa

https://doi.org/10.1016/j.ejphar.2018.09.011

open access

Abstract

Drug-target binding kinetics has recently attracted considerable interest in view of the potential predictive power for in vivo drug efficacy. The recently introduced antihistamine bilastine has a long duration of in vivo drug action, which outlasts pharmacological active bilastine concentrations in blood. To provide a molecular basis for the long duration of action, we explored the kinetics of bilastine binding to the human histamine H1 receptor using [3H]mepyramine binding studies and compared its pharmacodynamics properties to the reference compounds fexofenadine and diphenhydramine, which have a long (60 ± 20 min) and short (0.41 ± 0.1 min) residence time, respectively. Bilastine shows a long drug-target residence time at the H1 receptor (73 ± 5 min) and this results in a prolonged H1 receptor antagonism in vitro (Ca2+ mobilization in Fluo-4 loaded HeLa cells), following a washout of unbound antagonist. Hence, the long residence time of bilastine can explain the observed long duration of drug action in vivo.

Article PDF